{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:10:34Z","timestamp":1779253834380,"version":"3.51.4"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Tumor-infiltrating lymphocyte (TIL) therapy is an emerging treatment for patients with metastatic melanoma whose disease has progressed on immune checkpoint inhibitors. However, individuals living with well-controlled human immunodeficiency virus (HIV) have historically been excluded from clinical trials evaluating adoptive cell therapies, leaving uncertainty regarding safety, tolerability, immune effects, and oncologic response in this population. We present the first known case of a patient with virologically suppressed HIV receiving TIL therapy for immunotherapy-refractory metastatic melanoma. A 37-year-old man with long-standing HIV on antiretroviral therapy (ART) developed rapidly progressive, BRAF-V600E mutant metastatic melanoma involving bulky axillary disease and pulmonary metastases despite anti\u2013PD-1 therapy, combined checkpoint blockade, and BRAF\/MEK\u2013targeted therapy. His course prior to TIL therapy was notable for minimal treatment-related toxicities and intermittent detectable low-level HIV viremia. After multidisciplinary review, he underwent TIL harvest followed by lymphodepleting chemotherapy, lifileucel infusion, and high-dose interleukin-2 (IL-2). TIL therapy was tolerated with expected toxicities, including grade 1 cytokine release syndrome and IL-2\u2013associated grade 3 hypotension requiring brief vasopressor support. At day 44, imaging demonstrated a partial response with decreased pulmonary metastases and stabilization of axillary disease. Progression of disease was observed by day 86. CD4 counts fluctuated markedly throughout treatment, though virologic suppression was ultimately restored by day 100. This case demonstrates that TIL therapy can be feasibly administered to a patient with well-controlled HIV, with manageable toxicity and early radiographic response. These findings underscore the need for prospective inclusion of people living with HIV in cellular therapy trials to better characterize safety, immune dynamics, and predictors of durable benefit.<\/jats:p>","DOI":"10.3389\/fonc.2026.1818578","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:49:13Z","timestamp":1779252553000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["TIL cell therapy in HIV positive patient with metastatic melanoma: case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Brian","family":"Whetsell","sequence":"first","affiliation":[{"name":"Department of Comparative Human Development, The University of Chicago","place":["Chicago, IL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Alban","sequence":"additional","affiliation":[{"name":"McGaw Medical Center, Northwestern University","place":["Chicago, IL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam Y.","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University","place":["Chicago, IL, United States"]},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","place":["Chicago, IL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey D.","family":"Wayne","sequence":"additional","affiliation":[{"name":"Department of Surgery, Northwestern University Feinberg School of Medicine","place":["Chicago, IL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunandana","family":"Chandra","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University","place":["Chicago, IL, United States"]},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","place":["Chicago, IL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma","volume":"24","author":"Gide","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B2","article-title":"FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma","volume-title":"U.S. Food and Drug Administration","year":"2024"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144\u201301 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B4","unstructured":""},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13514","article-title":"Enabling CAR T-cell therapies for HIV-positive lymphoma patients - A call for action","volume":"24","author":"Hattenhauer","year":"2023","journal-title":"HIV Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10555-024-10230-6","article-title":"Melanoma in people living with HIV: Immune landscape dynamics and the role of immuno- and antiviral therapies","volume":"44","author":"Barger","year":"2024","journal-title":"Cancer Metast Rev"},{"key":"B7","article-title":"Melanoma of the Skin - cancer stat facts","volume-title":"SEER","year":"2025"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1268479","article-title":"Advances in melanoma: epidemiology, diagnosis, and prognosis","volume":"10","author":"Waseh","year":"2023","journal-title":"Front Med (Laus)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/op.21.00686","article-title":"Managing metastatic melanoma in 2022: A clinical review","volume":"18","author":"Switzer","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0279-5","article-title":"High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute","volume":"5","author":"Davar","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01066","article-title":"What, if any, role is there for BRAF-targeted therapy in BRAF-mutant melanoma","volume":"40","author":"Sullivan","year":"2022","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2019.1593806","article-title":"Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis","volume":"8","author":"Fu","year":"2019","journal-title":"Oncoimmunology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102836","article-title":"Treating cancer with immunotherapy in HIV-positive patients: A challenging reality","volume":"145","author":"Guaitoli","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.647688","article-title":"Epigenetic features of HIV-induced T-cell exhaustion persist despite early antiretroviral therapy","volume":"12","author":"Marin","year":"2021","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.827596","article-title":"Lymphocytes infiltration and expression of PD-1 and PD-L1 in colorectal cancer between HIV-infected and non-HIV-infected patients: A propensity score matched cohort study","volume":"12","author":"Cao","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3018(23)00202-3","article-title":"Skin cancer risk in people living with HIV: a call for action","volume":"11","author":"Reinhart","year":"2024","journal-title":"Lancet HIV"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2019.28","article-title":"Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors","volume":"2","author":"Fenton","year":"2019","journal-title":"Canc Drug Resist"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02498-y","article-title":"Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial","volume":"29","author":"VanderWalde","year":"2023","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/cmr.0000000000000832","article-title":"Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors","volume":"32","author":"Ismail","year":"2022","journal-title":"Melanoma Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2024.12.010","article-title":"Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation","volume":"27","author":"Amaria","year":"2025","journal-title":"Cytotherapy"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.27110","article-title":"Assessment of Cancer Therapy Evaluation Program advocacy and inclusion rates of people living with HIV in anti-PD1\/PDL1 clinical trials","volume":"3","author":"Reuss","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1818578\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:49:22Z","timestamp":1779252562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1818578\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1818578"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1818578","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1818578"}}